AffiliationDepartment of Medical Oncology, Christie Hospital, Manchester, U.K.
MetadataShow full item record
AbstractFifty Portacaths have been inserted in patients undergoing prolonged outpatient chemotherapy, most for haematological disease. Twenty-one are still working at a median duration of 12 months (range 1-27) and a further 15 were functioning normally at the time of the patients death (median survival 6 months). Four functioning Portacaths have been removed, three suspected of causing septicaemia and one believed erroneously to have occluded. Ten have ceased to function and nine of these have been removed. The causes of these failures are nearly all avoidable and are discussed in detail; many occurred early in our experience. With careful attention to detail and with management by trained and interested staff, the Portacath is a safe and reliable device for intermittent vascular access.
CitationExperience with the Portacath., 6 (1):57-63 Hematol Oncol
- Administration of chemotherapeutic agents. Techniques and controversies.
- Authors: Raaf JH
- Issue date: 1994 Nov
- Comparison of a totally implantable access device for chemotherapy (Port-A-Cath) and long-term percutaneous catheterization (Broviac).
- Authors: Greene FL, Moore W, Strickland G, McFarland J
- Issue date: 1988 May
- Peripherally inserted central catheters (PICCs) in cancer patients under chemotherapy: A prospective study on the incidence of complications and overall failures.
- Authors: Bertoglio S, Faccini B, Lalli L, Cafiero F, Bruzzi P
- Issue date: 2016 May
- Intravenous access in infants and children.
- Authors: Stovroff M, Teague WG
- Issue date: 1998 Dec
- [Permanent venous access through a +portacath reservoir in patients receiving prolonged chemotherapy].
- Authors: García H, Díaz R, Pablo Barés J, Nevah E, Fábrega JM
- Issue date: 1994 Jan